Capricor Therapeutics is challenging the FDA's briefing materials for its upcoming advisory committee meeting, stating they rely on an outdated analysis plan for their Duchenne muscular dystrophy drug, Deramiocel. This disagreement introduces uncertainty regarding the FDA's perception of the drug's efficacy ahead of a critical review.
Capricor Therapeutics is publicly disputing the FDA's briefing materials for the upcoming advisory committee meeting concerning their Duchenne muscular dystrophy drug, Deramiocel. The company claims the FDA's analysis relies on an 'obsolete' and 'incomplete' draft analysis plan (SAP version 1.1) rather than the final, unblinded version (SAP version 3.0). This is significant because the advisory committee's recommendation is a crucial step in the drug approval process, and a disagreement over the data analysis could sway their opinion. For traders, this introduces a short-term risk for CAPR as the market digests this information and anticipates the outcome of the advisory committee meeting. A negative recommendation could significantly impact the stock, while a successful rebuttal by Capricor could provide a boost. The long-term implications depend on the ultimate FDA decision.